---
title: "Scientific Industries, Inc. | 10-Q: FY2025 Q1 Revenue: USD 2.407 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/240060972.md"
datetime: "2025-05-13T20:39:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/240060972.md)
  - [en](https://longbridge.com/en/news/240060972.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/240060972.md)
---

# Scientific Industries, Inc. | 10-Q: FY2025 Q1 Revenue: USD 2.407 M

Revenue: As of FY2025 Q1, the actual value is USD 2.407 M.

EPS: As of FY2025 Q1, the actual value is USD -0.16.

EBIT: As of FY2025 Q1, the actual value is USD -1.779 M.

### Segment Revenue

-   **Benchtop Laboratory Equipment**: Revenue for the three months ended March 31, 2025, was $2,273,000, compared to $2,167,400 for the same period in 2024.
-   **Bioprocessing Systems**: Revenue for the three months ended March 31, 2025, was $133,500, compared to $316,100 for the same period in 2024.

### Operational Metrics

-   **Net Loss**: The net loss for the three months ended March 31, 2025, was -$1,778,500, compared to -$2,051,600 for the same period in 2024.
-   **Gross Profit**: Gross profit for the three months ended March 31, 2025, was $1,016,600, compared to $1,040,800 for the same period in 2024.
-   **Operating Expenses**: Total operating expenses for the three months ended March 31, 2025, were $2,827,500, compared to $3,130,300 for the same period in 2024.

### Cash Flow

-   **Operating Cash Flow**: Net cash used in operating activities for the three months ended March 31, 2025, was -$1,331,100, compared to -$1,565,100 for the same period in 2024.
-   **Investing Cash Flow**: Net cash provided by investing activities for the three months ended March 31, 2025, was $1,204,000, compared to $480,600 for the same period in 2024.

### Unique Metrics

-   **Foreign Sales**: Foreign sales for the three months ended March 31, 2025, were $577,200, compared to $855,600 for the same period in 2024.

### Future Outlook and Strategy

-   **Core Business Focus**: The company plans to continue cost-cutting initiatives in the Bioprocessing Systems Operations segment, which were initiated in fiscal 2024.
-   **Non-Core Business**: The company is exploring the sale of assets and securing additional capital resources to address liquidity concerns.

### Related Stocks

- [SCND.US](https://longbridge.com/en/quote/SCND.US.md)

## Related News & Research

- [Why VOO ETF Investors Don't Have to Worry About Buying SpaceX Stock Just Yet](https://longbridge.com/en/news/289506372.md)
- [Nvidia or Palantir: Top Investor Says Only One AI Stock Is a Strong Buy](https://longbridge.com/en/news/289524885.md)
- [Intel's stock could push even higher thanks to this subtle dynamic, BofA says](https://longbridge.com/en/news/289498064.md)
- [Microsoft Just Gave Investors 3 Dates They Can't Afford to Ignore](https://longbridge.com/en/news/289500746.md)
- [Oracle's stock is seeing its worst run in a quarter-century as this key AI debate rages on](https://longbridge.com/en/news/289491717.md)